[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]
- PMID: 17021905
- DOI: 10.1007/s00120-006-1211-7
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]
Abstract
Sunitinib and Sorafenib are both effective angiogenetic inhibitors for the treatment of renal cell carcinoma. With these drugs of a new class of chronic therapy is performed. During chronic treatment, the inherent side effects may necessitate stopping the application of these drugs thus preventing the required effective therapy. Most of the effects can be avoided or attenuated by prophylaxis. In this paper the published data are reviewed and added with our experience in 138 patients over up to two and a half years.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
